Status:
COMPLETED
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
Lead Sponsor:
AbbVie
Conditions:
Hepatitis C
Eligibility:
All Genders
Brief Summary
The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been sho...
Eligibility Criteria
Inclusion
- Participants are treatment-naïve or treatment-experienced with pegylatedinterferon (pegIFN), or IFN, and/or ribavirin (RBV) and/or sofosbuvir (PRS) with confirmed chronic hepatitis C (CHC), genotypes 1, 2, 3, 4, 5, or 6, with or without compensated cirrhosis, receiving combination therapy with the all oral glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
- Participants may be enrolled up to 4 weeks after treatment initiation
- Participants must not be participating or intending to participate in a concurrent interventional therapeutic trial.
Exclusion
- None.
Key Trial Info
Start Date :
November 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 24 2020
Estimated Enrollment :
2118 Patients enrolled
Trial Details
Trial ID
NCT03303599
Start Date
November 13 2017
End Date
January 24 2020
Last Update
May 19 2021
Active Locations (156)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum Klagenfurt am Woerthersee, Apotheke /ID# 169931
Klagenfurt, Carinthia, Austria, 9020
2
University Hospital St. Polten /ID# 169918
Sankt Pölten, Lower Austria, Austria, 3100
3
Medizinische Universität Graz /ID# 169932
Graz, Styria, Austria, 8020
4
Landeskrankenhaus Hall /ID# 169930
Hall in Tirol, Tyrol, Austria, 6060